Our articles are based on guidance from U.S. public health agencies and peer-reviewed medical research. These are the main sources our physicians use. Links open the original publisher's page.
HIV prevention (PrEP and PEP)
- Tanner MR, O'Shea JG, Byrd KM, et al. Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV: CDC Recommendations, United States, 2025. MMWR Recommendations and Reports, 2025;74(RR-1). cdc.gov/mmwr/volumes/74/rr/rr7401a1.htm
- Patel RR, Hoover KW, Lale A, et al. Clinical Recommendation for the Use of Injectable Lenacapavir as HIV Preexposure Prophylaxis, United States, 2025. MMWR, September 18, 2025. cdc.gov/mmwr/volumes/74/wr/mm7435a1.htm
- CDC. Preexposure Prophylaxis for the Prevention of HIV Infection in the United States, 2021 Update: A Clinical Practice Guideline. stacks.cdc.gov/view/cdc/112360
- U.S. FDA. Yeztugo (lenacapavir) prescribing information (approved June 2025). dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1c241af1-ce62-4b0a-9eb7-f6b626174f01
- Horberg M, et al. Primary Care Guidance for Providers Who Care for Persons With Human Immunodeficiency Virus: 2024 Update by the HIV Medicine Association of the Infectious Diseases Society of America. Clinical Infectious Diseases, 2024. doi.org/10.1093/cid/ciae479
- For patients: HIVinfo, National Institutes of Health. hivinfo.nih.gov
Bacterial STI prevention (doxy-PEP)
- Bachmann LH, Barbee LA, Chan P, et al. CDC Clinical Guidelines on the Use of Doxycycline Postexposure Prophylaxis for Bacterial Sexually Transmitted Infection Prevention, United States, 2024. MMWR Recommendations and Reports, 2024;73(RR-2). cdc.gov/mmwr/volumes/73/rr/rr7302a1.htm
- Luetkemeyer AF, et al. Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted Infections. New England Journal of Medicine, 2023;388:1296–1306. pubmed.ncbi.nlm.nih.gov/37018493
STI treatment and national trends
- Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recommendations and Reports, 2021;70(RR-4). cdc.gov/std/treatment-guidelines
- CDC. Sexually Transmitted Infections Surveillance, 2024 (Provisional). Published September 24, 2025. cdc.gov/sti-statistics
- U.S. FDA. Blujepa (gepotidacin) prescribing information. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=80b57cfe-7819-4d95-a57d-014af42f118d
- U.S. FDA. Nuzolvence (zoliflodacin) prescribing information (approved December 12, 2025). dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4beda35a-21b0-4b34-84ea-be6ea8cae50f
Hepatitis C
- U.S. Preventive Services Task Force. Screening for Hepatitis C Virus Infection in Adolescents and Adults: Recommendation Statement. 2020. uspreventiveservicestaskforce.org
- Schillie S, et al. CDC Recommendations for Hepatitis C Screening Among Adults, United States, 2020. MMWR Recommendations and Reports, 2020;69(RR-2). cdc.gov/mmwr/volumes/69/rr/rr6902a1.htm
Sepsis
- Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA, 2016;315(8):801–810. pubmed.ncbi.nlm.nih.gov/26903338
- For patients: CDC. Sepsis. cdc.gov/sepsis
Bone, joint and foot infections; IV versus oral antibiotics
- Li HK, Rombach I, Zambellas R, et al. Oral versus Intravenous Antibiotics for Bone and Joint Infection. New England Journal of Medicine, 2019;380:425–436. pubmed.ncbi.nlm.nih.gov/30699315
- Scarborough M, Li HK, Rombach I, et al. Oral versus intravenous antibiotics for bone and joint infections: the OVIVA non-inferiority RCT. Health Technology Assessment, 2019;23(38). pubmed.ncbi.nlm.nih.gov/31373271
- Lima JPC, Chagas KA, Oliveira LBP, Filho BSB, Vital FMR. Oral Versus Intravenous Antibiotics for Bone and Joint Infections: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Bone, 2025. pubmed.ncbi.nlm.nih.gov/40280255
Fungal infections
- Denning DW. Global incidence and mortality of severe fungal disease. Lancet Infectious Diseases, 2024;24(7):e428–e438. pubmed.ncbi.nlm.nih.gov/38224705
Antibiotic resistance and MRSA
- GBD 2021 Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050. The Lancet, 2024. pubmed.ncbi.nlm.nih.gov/39299261
- CDC. Be Antibiotics Aware: Smart Use, Best Care. cdc.gov/antibiotic-use
- CDC. Antibiotic Resistance Threats in the United States, 2019. stacks.cdc.gov/view/cdc/82532
Mpox
- Zucker J, Fischer WA, Zheng L, et al. Tecovirimat for the Treatment of Mpox (STOMP). New England Journal of Medicine, 2026. pubmed.ncbi.nlm.nih.gov/41740032
- CDC. Mpox: clinical treatment. cdc.gov/mpox/hcp/clinical-care
Lyme disease
- CDC. About Southern Tick-Associated Rash Illness (STARI). cdc.gov/lyme/about/about-southern-tick-associated-rash-illness.html
- Mead P, Petersen J, Hinckley A. Updated CDC recommendation for serologic diagnosis of Lyme disease. MMWR, 2019;68(32):703. cdc.gov/mmwr/volumes/68/wr/mm6832a4.htm
- Lantos PM, et al. IDSA/AAN/ACR 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease. Clinical Infectious Diseases, 2021. doi.org/10.1093/cid/ciaa1215
Post-COVID
- National Academies of Sciences, Engineering, and Medicine. A Long COVID Definition: A Chronic, Systemic Disease State with Profound Consequences. 2024. nap.nationalacademies.org
- RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. New England Journal of Medicine, 2021;384:693–704. pubmed.ncbi.nlm.nih.gov/32678530
Urinary tract infections
- U.S. FDA. Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections. May 12, 2016. (Official FDA Archive copy.) fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-advises-restricting-fluoroquinolone-antibiotic-use-certain
- Anger J, et al. Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline. Journal of Urology, 2019 (amended 2022). auanet.org/guidelines
Travel health
- CDC Yellow Book: Health Information for International Travel. cdc.gov/yellow-book
- CDC. Dengue. cdc.gov/dengue
- CDC. Malaria: clinical guidance. cdc.gov/malaria/hcp
- Florida Department of Health. Vibrio vulnificus. floridahealth.gov/diseases-and-conditions/disease/vibrio-infections
Crisis and emergency
- 988 Suicide & Crisis Lifeline: call or text 988. 988lifeline.org
- For any medical emergency, call 911.
Medically reviewed by the physicians of Florida ID Care. Last reviewed November 12, 2026.
This page is for education and is not a substitute for medical care. Call 911 for a medical emergency, or call or text 988 for a mental health crisis.
Links to outside sites are provided for information and do not imply endorsement.
